Gamification - turning boring, unpleasant but necessary tasks into an online game - is a new way of thinking that is gaining momentum among drugmakers and health campaigners.
The emergence of drug-resistant or superbug strains of gonorrhoea is caused by unregulated access to and overuse of antibiotics, which helps fuel natural genetic mutations within the bacteria.
GlaxoSmithKline Plc (NYSE: GSK) will begin a $2.6 billion hostile takeover bid for Human Genome Sciences (NASDAQ: HGSI), the company announced Wednesday.
Stock index futures pointed to a lower open on Wall Street on Wednesday, with futures for the S&P 500 down 0.6 percent, Dow Jones futures 0.3 percent weaker, and Nasdaq 100 futures off 0.5 percent at 04:54 a.m. EDT (0854 GMT).
When Odei Antwi-Agyei had the chance of introducing vaccines to prevent Ghana's children dying of diarrhea, or vaccines to stop them dying of pneumonia, he did what no African immunization chief has done before. He said he'd do both at the same time.
Drugmaker GlaxoSmithKline said on Wednesday its $2.6 billion bid for long-time partner Human Genome Sciences was full and fair and it was the only obvious owner for the biotechnology firm.
Drugmaker GlaxoSmithKline said on Wednesday its $2.6 billion bid for long-time partner Human Genome Sciences was full and fair and it was the only obvious owner for the biotechnology firm.
Drugmaker GlaxoSmithKline said on Wednesday its $2.6 billion bid for long-time partner Human Genome Sciences was full and fair and it was the only obvious owner for the U.S. biotechnology firm.
Human Genome Sciences Inc , which rebuffed an unsolicited $2.6 billion takeover bid by British drugmaker GlaxoSmithKline , said on Tuesday it was reviewing strategic alternatives, including the sale of the company.
AstraZeneca has agreed to buy U.S. company Ardea Biosciences for $1.26 billion, giving it a new gout drug to bolster its weak pipeline in a deal that feeds a wave of M&A in the biotechnology sector.
Human Genome Sciences has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector swept by M&A activity recently.
Human Genome Sciences Inc has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline Plc, marking a new takeover battle in a drugs sector that has been swept by M&A recently.
Human Genome Sciences Inc said on Thursday its long-time partner GlaxoSmithKline Plc had made an unsolicited proposal to buy it for $13.00 per share in cash, a move underscoring the rapid pace of deal-making in pharmaceuticals.
The pharmaceutical industry is paying close attention to a case that could determine if about 90,000 sales representatives are entitled to overtime pay.
The top after-market NASDAQ gainers Friday were: Cornerstone OnDemand, TASER International, MAP Pharmaceuticals, Affymax, Avis Budget Group and Steel Dynamics. The top after-market NASDAQ losers were: Pacific Biosciences of California, Targacept, Ancestry.com, Theravance, Vocus and Commercial Vehicle Group.
James Murdoch has severed all ties with News Corp's British newspaper business, which is at the centre of multiple investigations over phone and computer hacking and bribery, according to regulatory filings.
